Wells Fargo lowered the price target for the Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) stock from “an Overweight” to “an Equal weight”. The rating was released on September 30, 2020. In their research brief published February 25, 2019, H.C. Wainwright analysts upgraded the Ironwood Pharmaceuticals Inc. stock from Sell to Neutral with a price target of $14.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) dipped -0.57% to close Thursday’s market session at $13.84, lower as compared to yesterday’s close. The stock price fluctuated between $13.81 and $14.27 throughout the trading session with the volume trading being 2368416 shares, which represented a significant variation when compared to the three months average volume of 1.94 million shares. The firm’s stock price fluctuated 4.14% within the last five trades and 11.25% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 36.76% in the last 6 months and 20.56% was added to its value over the previous 3 months. IRWD stock is trading at a margin of 5.52%, 10.33% and 21.73% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, IRWD deals in the Healthcare domain. The stock is trading -0.65 percent below its 52-week high and 60.37 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 45.48. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Ironwood Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 35.90 percent and the profit margin is 26.60 percent, and the company has reported a gross margin of 99.80 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $2.23 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is 15.64. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 8.38. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 5.60 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 20.35, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Currie Mark G, the Director at Ironwood Pharmaceuticals Inc. (IRWD) has sold 23,571 shares of firm on Jun 14 at a price of $11.59 against the total amount of $0.27 million. In another inside trade, MCCOURT Thomas A, President and Interim CEO of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) sold 1,716 shares of the firm on May 24 for a total worth of $21021.0 at a price of $12.25. An inside trade which took place on May 24, CMO, SVP & Head of Drug Devt. of Ironwood Pharmaceuticals Inc. Shetzline Michael sold 2,077 shares of firm against total price of $25443.0 at the cost of $12.25 per share.